Stockscreener 앱 받기
9.42
5.07%
-0.53
전일 마감가:
$9.95
열려 있는:
$9.97
하루 거래량:
1.21M
Relative Volume:
0.43
시가총액:
$1.07B
수익:
-
순이익/손실:
$-294.51M
주가수익비율:
-2.6461
EPS:
-3.56
순현금흐름:
$-244.42M
1주 성능:
+3.01%
1개월 성능:
-1.30%
6개월 성능:
-29.82%
1년 성능:
-78.79%
1일 변동 폭
$9.26
$9.97
1주일 범위
$9.00
$10.23
52주 변동 폭
$6.36
$47.45
다인 테라 Stock (DYN) Company Profile
명칭
Dyne Therapeutics Inc
전화
(781) 786-8230
주소
1560 TRAPELO ROAD, WALTHAM
DYN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
9.42 | 1.41B | 0 | -294.51M | -244.42M | -3.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.92 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.13 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.21 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
596.79 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
297.98 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
다인 테라 Stock (DYN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-24 | 개시 | Bernstein | Mkt Perform |
| 2025-06-11 | 재개 | Raymond James | Outperform |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-29 | 개시 | Evercore ISI | Outperform |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-13 | 개시 | Robert W. Baird | Outperform |
| 2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-10-24 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-05-21 | 재확인 | Chardan Capital Markets | Buy |
| 2024-04-30 | 개시 | Morgan Stanley | Overweight |
| 2024-02-20 | 개시 | H.C. Wainwright | Buy |
| 2023-02-27 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | 개시 | Oppenheimer | Outperform |
| 2023-01-26 | 개시 | Guggenheim | Buy |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Outperform |
| 2020-10-12 | 개시 | JP Morgan | Overweight |
| 2020-10-12 | 개시 | Jefferies | Buy |
| 2020-10-12 | 개시 | Piper Sandler | Overweight |
| 2020-10-12 | 개시 | Stifel | Buy |
모두보기
다인 테라 주식(DYN)의 최신 뉴스
Why is Dyne Therapeutics Inc. stock attracting strong analyst attentionUnlock exclusive trading strategies for gains - jammulinksnews.com
How many analysts rate Dyne Therapeutics Inc. as a “Buy”Exceptional market positioning - jammulinksnews.com
What is the risk reward ratio of investing in Dyne Therapeutics Inc. stockDiscover breakthrough investment opportunities - jammulinksnews.com
What is Dyne Therapeutics Inc. company’s growth strategyDiscover market opportunities with expert help - jammulinksnews.com
Should I hold or sell Dyne Therapeutics Inc. stock in 2025Breakthrough investment results - jammulinksnews.com
What makes Dyne Therapeutics Inc. stock price move sharplyRecord-setting profit potential - jammulinksnews.com
What are analysts’ price targets for Dyne Therapeutics Inc. in the next 12 monthsGet insider insights into market trends - jammulinksnews.com
What is the dividend policy of Dyne Therapeutics Inc. stockFind the best stocks for sustainable growth - jammulinksnews.com
What are the technical indicators suggesting about Dyne Therapeutics Inc.Track emerging stocks with high growth potential - jammulinksnews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - WV News
Dyne Therapeutics Inc. Stock Analysis and ForecastBreakout profit opportunities - Autocar Professional
What analysts say about Dyne Therapeutics Inc. stockFree Stock Market Return Analysis - Autocar Professional
What drives Dyne Therapeutics Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com
Is Dyne Therapeutics Inc. a good long term investmentGame-changing returns - Autocar Professional
Dyne Therapeutics (NASDAQ:DYN) Price Target Lowered to $9.00 at JPMorgan Chase & Co. - MarketBeat
Hedge Fund and Insider Trading News: Bill Ackman, Warren Buffett, Ray Dalio, Scott Bessent, Elliott Management, Citadel Investment Group, Balyasny Asset Management, Qualys Inc (QLYS), Dyne Therapeutics Inc (DYN), and More - Insider Monkey
Dyne Therapeutics (DYN) Stock Rises as CEO Increases Stake - GuruFocus
Dyne shares up after CEO buys stock (DYN:NASDAQ) - Seeking Alpha
Former Biogen VP Who Led SPINRAZA Success Joins Satellos to Advance DMD Treatment - Stock Titan
Dyne Therapeutics price target lowered to $41 from $46 at Evercore ISI - MSN
Strategic Confidence in Dyne Therapeutics: Insider Backing and Breakthroughs in Rare Disease Therapies - AInvest
DYN CEO Makes Significant Stock Purchase, Shares Rise | DYN Stoc - GuruFocus
How to Take Advantage of moves in (DYN) - news.stocktradersdaily.com
Evercore ISI Analyst Lowers Dyne Therapeutics Price Target to $41, Maintains Outperform Rating - AInvest
RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT - Yahoo Finance
Dyne Therapeutics (DYN) Sees Price Target Reduced by Evercore IS - GuruFocus
Dyne Therapeutics’ DYNE-251 Study Update: A Potential Game-Changer for Duchenne Muscular Dystrophy - TipRanks
RBC Capital Sticks to Their Buy Rating for Dyne Therapeutics (DYN) - The Globe and Mail
다인 테라 (DYN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.56%
1.19%
자본화:
|
볼륨(24시간):